Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2026-05-11 Major Shareholding Noti…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a disclosure of a change in shareholding by The Capital Group Companies, Inc. in Vicore Pharma Holding AB, providing pre-transaction and post-transaction share counts and voting rights in compliance with the Swedish Financial Supervisory Authority’s major shareholding notification rules (FITA Ch. 4). It is a classic Major Shareholding Notification rather than an earnings release or regulatory filing. Therefore, it matches category MRQ.
2026-05-11 English
Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 95% confidence The document is a press release dated 6 May 2026, detailing resolutions passed at the Annual General Meeting (AGM) of Vicore Pharma Holding AB. It includes adoption of financial statements, election of board members, approval of remuneration reports, authorization to issue shares, and adoption of equity-based incentive programs. The content is typical of AGM announcements summarizing meeting outcomes and shareholder decisions. The document does not contain full financial statements or detailed financial performance data, but rather the results and decisions made at the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length (9547 characters) supports it being a detailed announcement rather than a brief notice or a full annual report.
2026-05-06 English
Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)
AGM Information Classification · 95% confidence The document is a press release dated May 6, 2026, reporting on the decisions made at the Annual General Meeting (AGM) of Vicore Pharma Holding AB. It includes resolutions on approval of financial statements, election of board members and auditors, approval of remuneration reports, authorization for share issuance, and implementation of share-based incentive programs. The content is typical of AGM minutes or communications summarizing shareholder decisions and board elections rather than the full annual report or financial statements themselves. The document is not the full Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is a detailed communication of AGM outcomes, which fits the category AGM Information (AGM-R).
2026-05-06 Swedish
KALLELSE TILL ÅRSSTÄMMA I VICORE PHARMA HOLDING AB (PUBL)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice (“kallelse”) convening the Annual General Meeting, including agenda items, participation instructions, proxy forms, and voting procedures. This constitutes materials sent to shareholders to inform and solicit votes for the meeting rather than the meeting results or a published report. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-04-01 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN VICORE PHARMA HOLDING AB (PUBL)
Proxy Solicitation & Information Statement Classification · 94% confidence The document is a detailed notice and information statement for the Annual General Meeting, including the meeting date, venue, record date, registration and advance voting procedures, agenda items, and proposed resolutions (proxy form instructions, voting by mail). It is not the AGM presentation itself but rather the proxy solicitation/information statement sent to shareholders to inform and request votes. Therefore, it best fits the Proxy Solicitation & Information Statement category.
2026-04-01 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2025' which translates to 'Annual Report 2025' for Vicore Pharma Holding AB. It contains detailed sections typical of an annual report, including a letter from the CEO (VD-ord), financial statements, notes, audit report (Revisionsberättelse), corporate governance report (Bolagsstyrningsrapport), and detailed financial data for the year 2025. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial results, business overview, clinical study updates, and regulatory milestones, all consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-03-26 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.